Equities

WELL Health Technologies Corp

WELL Health Technologies Corp

Actions
Health CareHealth Care Providers
  • Price (CAD)5.12
  • Today's Change0.150 / 3.02%
  • Shares traded1.46m
  • 1 Year change+20.19%
  • Beta1.2096
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform12
Hold1
Sell0
Strong Sell0

Share price forecast in CAD

The 15 analysts offering 12 month price targets for WELL Health Technologies Corp have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 5.25. The median estimate represents a 56.25% increase from the last price of 5.12.
High95.3%10.00
Med56.3%8.00
Low2.5%5.25

Earnings history & estimates in CAD

On Nov 07, 2024, WELL Health Technologies Corp reported 3rd quarter 2024 losses of -0.33 per share.
The next earnings announcement is expected on Mar 19, 2025.
Average growth rate+283.33%
WELL Health Technologies Corp reported annual 2023 breakeven earnings per share on Mar 21, 2024.
Average growth rate-201.39%
More ▼

Revenue history & estimates in CAD

WELL Health Technologies Corp. had 3rd quarter 2024 revenues of 251.74m. This bettered the 248.27m consensus of the 14 analysts covering the company. This was 48.58% above the prior year's 3rd quarter results.
Average growth rate+5.44%
WELL Health Technologies Corp. had revenues for the full year 2023 of 776.05m. This was 36.36% above the prior year's results.
Average growth rate+169.87%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.